000 01500 a2200397 4500
005 20250515010215.0
264 0 _c20060215
008 200602s 0 0 eng d
022 _a1056-4993
024 7 _a10.1016/j.chc.2005.08.007
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aCorrell, Christoph U
245 0 0 _aRecognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
_h[electronic resource]
260 _bChild and adolescent psychiatric clinics of North America
_cJan 2006
300 _a177-206 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Review
650 0 4 _aAdolescent
650 0 4 _aAntipsychotic Agents
_xadverse effects
650 0 4 _aBasal Ganglia Diseases
_xchemically induced
650 0 4 _aBody Mass Index
650 0 4 _aChild
650 0 4 _aDyslipidemias
_xchemically induced
650 0 4 _aHumans
650 0 4 _aMental Disorders
_xdrug therapy
650 0 4 _aMetabolic Syndrome
_xchemically induced
650 0 4 _aProlactin
_xmetabolism
650 0 4 _aRecognition, Psychology
700 1 _aPenzner, Julie B
700 1 _aParikh, Umesh H
700 1 _aMughal, Tahir
700 1 _aJaved, Tariq
700 1 _aCarbon, Maren
700 1 _aMalhotra, Anil K
773 0 _tChild and adolescent psychiatric clinics of North America
_gvol. 15
_gno. 1
_gp. 177-206
856 4 0 _uhttps://doi.org/10.1016/j.chc.2005.08.007
_zAvailable from publisher's website
999 _c15943997
_d15943997